Jupiter Neurosciences (JUNS) said late Monday it has priced an initial public offering of about 2.8 million shares of common stock at $4 per share.
The shares are expected to begin trading Tuesday on the Nasdaq market under the symbol "JUNS." The offering is expected to close Wednesday.
The company said it expects to receive gross proceeds of $11 million and intends to use them to fund a phase 2 clinical trial of its drug candidate Jotrol in patients with Parkinson's Disease, among other things.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments